Literature DB >> 8097497

Absence of HTLV-I infection among seronegative subjects in an endemic area of Japan.

T Kinoshita1, J Imamura, H Nagai, M Ito, S Ito, S Ikeda, M Nagatomo, K Tajima, K Shimotohno.   

Abstract

To examine the prevalence of infection by human T-cell leukemia virus type I (HTLV-I) among seronegative subjects, healthy subjects on Tsushima Island, Japan, where the infection is endemic, were evaluated. A total of 209 healthy adults were examined for HTLV-I provirus in peripheral blood mononuclear cells by the polymerase chain reaction (PCR), as well as for anti-HTLV-I antibodies by the particle agglutination (PA) method, the enzyme-linked immunosorbent assay (ELISA) and by immunofluorescence analysis (IF). A total of 76 subjects were positive and 133 were negative for the provirus, showing a close correlation with the results of 3 assays for anti-HTLV-I serum antibodies. None of the seronegative subjects reacted positively on PCR analysis. These observations indicate that seronegative HTLV-I carriers are rare in an area of Japan in which this viral infection is endemic.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097497     DOI: 10.1002/ijc.2910540104

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Evaluation of commercial HTLV-1 test kits by a standard HTLV-1 serum panel.

Authors:  C Fujiyama; T Fujiyoshi; D Matsumoto; H Tamashiro; S Sonoda
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

2.  Mortality among inhabitants of an HTLV-I endemic area in Japan.

Authors:  K Iwata; S Ito; H Saito; M Ito; M Nagatomo; T Yamasaki; S Yoshida; H Suto; K Tajima
Journal:  Jpn J Cancer Res       Date:  1994-03

3.  Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors.

Authors:  K Arisawa; M Soda; M Akahoshi; T Matsuo; E Nakashima; M Tomonaga; H Saito
Journal:  Jpn J Cancer Res       Date:  1998-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.